Liver DiseasesNCT05770284
Effect of Exercise Based Regimen on Frailty in Children With Liver Disease
A study testing 12 weeks exercise and Standard Medical Treatment in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
Trial summary
Frailty is now a well-known complication of liver disease and various studies, including pediatric literature studies, have recognized it as a poor prognostic factor in CLD as well as liver transplant settings. It is associated with poor quality of life, increased hospitalisation and mortality. Read more about this study
- Who is it for?
- Ages 9 to 18 years
- Conditions the study is for
- Liver Diseases
- What is being tested?
- 12 weeks exercise and Standard Medical Treatment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteIndia
- Study dates
- 15 Mar 2023to 2 Nov 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 9 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Children 9 - 18 years age with chronic liver disease \& frailty score > 5.
Who cannot join
- Lansky play performance scale <50
- Unable to do exercise under supervision on at least 2 occasions
- Children on higher corticosteroid dose (>0.1mg/kg/day) in last 12 weeks
- Any degree of musculoskeletal involvement (myopathy/limb deformity/paraplegia)
- Children with any cardiac disease
- Children with neurological Wilson
Show all 13Show fewer
- Uncontrolled portal hypertension (persistent high-risk varices) Recurrent variceal bleed ≥ 2
- Any degree of hemodynamic instability
- Current hepatic encephalopathy (any grade)
- Grade 3 ascites
- Hepatic hydrothorax
- Any degree of oxygen dependence
- Severe or Very severe Hepatopulmonary syndrome (room air PaO2 < 60 mm Hg).
Trial locations and contacts
1 site in 1 country.
India1 site
Institute of Liver & Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070
About this study
Official title: Effect of Exercise Based Regimen on Frailty in Children With Liver Disease -A Randomized Controlled Trial
Frailty is now a well-known complication of liver disease and various studies, including pediatric literature studies, have recognized it as a poor prognostic factor in CLD as well as liver transplant settings. It is associated with poor quality of life, increased hospitalisation and mortality. Exercise for >12 weeks leads to improvements in aerobic power (peak VO2), aerobic endurance, muscle mass and strength, health related quality of life (HRQoL)(1). Although effect of Exercise on sarcopenia and frailty has been studied extensively in cirrhotic adults, there is paucity of such literature on the effect of exercise on frailty in children. Through this study, we aim to assess efficacy of exercise-based regimen on frailty in children with chronic liver disease after 12 weeks. Our secondary objective will be to compare outcome between the two groups(frail and non frail children with liver disease) and to compare change in frailty scores between the two groups. Other objectives will include assessment of the body composition analysis and the myokines and hepatokines signatures of children with liver disease (pre and post exercise intervention).
Read the detailed description
Methodology Study population: Children with liver disease fulfilling the conditions as per inclusion and exclusion criteria
Baseline parameters that will be recorded:
- Clinical parameters:
- History and etiology of liver disease
- Symptomatology, Evidence of decompensation (jaundice, organomegaly, encephalopathy, ascites, infections, variceal bleed etc)
- PELD, MELD Na score, Lansky play performance score
- Baseline laboratory parameters: Complete blood count, LFT, KFT, PT-INR, ammonia etc
- Imaging parameters: liver and spleen size, portal vein size etc
- Anthropometric parameters:
- Weight for age
- Height for age
- BMI
- Triceps skin fold thickness
- Subscapular fold thickness
- Mid arm circumference
Calculation of frailty score:
Cut-off for frailty will be defined as frailty score >5 in children with liver disease.
Methodology for Frailty assessment:
Assessment of the 5 Fried Frailty Criteria would be performed at baseline in an ambulatory setting .The Fried Frailty assessment would be done in children with liver disease. The assessments will be typically performed by a combination of a doctor, dietician and physiotherapist.
Weakness-Grip strength would be measured using a handheld device, the Jamar Hand Dynamometer. The device would be squeezed 3 times by each hand, and the mean value of the recorded strength (in pounds) was taken as the final result and compared with standard values for age and sex. Slownessor endurance would be assessed by the 6-minute walk test (6-MWT). Children will use a standard hand wheel to capture the walked distance on a hard flat surface at their own pace. The covered distance expressed in meters (m) will be compared with standard values for sex and age. Shrinkage in children would be assessed by triceps skin fold thickness (TSF) measurements. TSF would be measured in triplicates by a dietician and the mean result was recorded in centimeters (cm) and compared with the Center for Disease Control age and sex normative values. Exhaustion-the Pediatric Quality of Life Inventory 4.0 Multidimensional Fatigue Scale, a validated pediatric questionnaire, would be used to assess fatigue. Diminished Physical activity-For children the age appropriate versions of the validated Modified Physical Activity Questionnaire (PAQ) (PAQ-A for children >13 years of age and PAQ-C for children< 13 yearof age will be used .
Along with routine investigations including Complete Blood counts, Liver function and Renal function test, PT-INR, serum Ammonia, the following investigations will also be done:
- Myokines (myostatin, decorin, irisin) and hepatokines (follistatin) levels in blood and urine at baseline and after 12 weeks of exercise therapy in study 2.
- Body composition analysis: Following parameters would be assessed: skeletal Muscle Mass; Body fat Mass; whole Body phase angle; segmental lean Analysis at baseline and after 12 weeks of exercise therapy in study 2.
Following enrolment and those fulfilling inclusion criteria, patient will then be allocated into exercise with SMT or SMT alone group as per block randomization method. Exercise with SMT or SMT alone will be given for a period of 12 weeks. Patient will be followed up for a period of 12 weeks. At the end of 12 weeks, frailty score will be recalculated .Body composition analysis,myokines and hepatokines will be repeated after 12 weeks.
Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed and overall hospital stay as well as mortality over 12 weeks and 6 months will be noted in both groups during this period and treated as per standard of care. These events will be defined as follows-
- Acute Kidney Injury As per KDIGO guidelines:
- Increase in serum creatinine by more than 0.3mg/dl within 48 hours, OR
- Urine output less than 0.5ml/kg/hour for more than 6 hours, OR
- Increase in serum creatinine by more than 1.5 times the baseline presumed/known to have occurred within prior 7 days.
- Hepatic encephalopathy: as per Modified West-Haven's criteria.
- Grades of ascites Grade 1- ascites only detected by ultrasound Grade 2 -moderate ascites evident by distension of abdomen with shifting dullness Grade 3- gross/tense ascites with marked abdominal distension Study period: 2 years
Intervention (Study 2):
- Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc
- Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)
- Aerobic exercises consist of Brisk walking
- Resistance Exercises consist of movements targeting the major muscle groups with weight lifting
- Intensity:
Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.
- Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength End point: 12 weeks
Stopping rule:
- Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.
- Progression to exclusion criteria i.e. decompensation etc Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day, and this will be ensured in regular follow-up as a standard care of practice developed by the department of Pediatric Hepatology.
Monitoring and assessment:
Patients will be followed up for a period of at least 3 months. Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed, significant infections will be noted in both groups during this period and treated as per standard of care.
At the end of 12 weeks, frailty assessment will be repeated along with myokines and hepatokines, body composition analysis and anthropometric examination.
Adverse effects:
There are no expected adverse effects of exercise as seen in previous studies.
Stopping rule of study:
- Interruption of exercise for more than 7 consecutive days due to non-compliance or clinical events.
- Progression to exclusion criteria i.e decompensation
- Potential liver transplant within 1 month.
- Conditions
- Liver Diseases
- Being tested
- 12 weeks exercise, Standard Medical Treatment
- Medical subject headings
- Liver Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
12 weeks exerciseOther
12 weeks exercise
Standard Medical TreatmentOther
Standard Medical Treatment
| Study group | Role | What they receive |
|---|---|---|
| Subject will receive 12 weeks of exercise with standard medical management (SMT) | Experimental | * Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc
* Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)
* Aerobic exercises consist of Brisk walking
* Resistance Exercises consist of movements targeting the major muscle groups with weight lifting
* Intensity:
Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.
* Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength
* End point: 12 weeks
* Stopping rule:
* Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.
* Progression to exclusion criteria i.e. decompensation etc
Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day Receives: Other: 12 weeks exercise; Other: Standard Medical Treatment |
| standard medical management (SMT) | Active comparator | standard medical management (SMT) Receives: Other: Standard Medical Treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Frailty in children with liver disease.
Fraility assessment criteria will be based on 5 elements:
- weakness will be assessed by grip strength.
- slowness will be by 6 minutes walk test.
- shrinkage by triceps fold thickness.
- exhaustion by validated pediatric PedsQL 4.0 multidiamential fatigue scale.
- diminshed physical activity by modified PAQ
Measured: 0 day
Improvement in Frailty after 12 weeks of exercise therapy in children with CLD and Frailty.
Improvement will be based on five fried fraility criteria with fraility score> 5
Measured: 12 weeks
Secondary outcomes (9)
Increase in skeletal muscle mass in Body composition analysis after 12 weeks of exercise regimen
Measured: 12 weeks
Decrease in the occurrence of Hepatic Encephalopathy based on modified West Haven criteria in the exercise regimen with SMT group versus SMT alone.
Measured: 3 months
Decrease in the occurrence of Upper Gastrointestinal bleed (presence or absence of GI bleed) in the exercise regimen with SMT group versus SMT alone.
Measured: 3 months
Decrease in the occurrence of significant events including Spontaneous Bacterial Peritonitis in the exercise regimen with SMT group versus SMT alone .
Measured: 3 months
Decrease in the occurrence of significant events including Acute Kidney Injury in the exercise regimen with SMT group versus SMT alone .
Measured: 3 months
Decrease in the occurrence of significant events including new onset or increase in ascites in the exercise regimen with SMT group versus SMT alone .
Measured: 3 months
Decrease in the occurrence of significant events including hospital stay in the exercise regimen with SMT group versus SMT alone .
Measured: 3 months
Decrease in the occurrence of significant events including mortality in the exercise regimen with SMT group versus SMT alone .
Measured: 3 months
Decrease in myostatin levels after 12 weeks of exercise regimen
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2023
- Study start15 Mar 2023
- Primary completion2 Nov 2024
- Study completion2 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver DiseasesStudies of the same condition, open and under way.
- More trials run by Institute of Liver and Biliary Sciences, IndiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05770284
- Sponsor's protocol ID
- ILBS-Liver Disease-02
- Status last verified
- Jan 2025
- First submitted
- 8 Feb 2023
- Last updated
- 8 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Exercise Based Regimen on Frailty in Children With Liver Disease -A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05770284
- Acronym / sponsor ID
- ILBS-Liver Disease-02
- Conditions
- Liver Diseases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Institute of Liver and Biliary Sciences, IndiaUniversity, hospital or other
- Study start
- 15 Mar 2023 (actual)
- Primary completion
- 2 Nov 2024 (actual)
- Study completion
- 2 Nov 2024 (actual)
- First posted
- 15 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Frailty is now a well-known complication of liver disease and various studies, including pediatric literature studies, have recognized it as a poor prognostic factor in CLD as well as liver transplant settings. It is associated with poor quality of life, increased hospitalisation and mortality. Exercise for >12 weeks leads to improvements in aerobic power (peak VO2), aerobic endurance, muscle mass and strength, health related quality of life (HRQoL)(1). Although effect of Exercise on sarcopenia and frailty has been studied extensively in cirrhotic adults, there is paucity of such literature on the effect of exercise on frailty in children. Through this study, we aim to assess efficacy of exercise-based regimen on frailty in children with chronic liver disease after 12 weeks. Our secondary objective will be to compare outcome between the two groups(frail and non frail children with liver disease) and to compare change in frailty scores between the two groups. Other objectives will include assessment of the body composition analysis and the myokines and hepatokines signatures of children with liver disease (pre and post exercise intervention).
Detailed description
Methodology Study population: Children with liver disease fulfilling the conditions as per inclusion and exclusion criteria
Baseline parameters that will be recorded:
- Clinical parameters:
- History and etiology of liver disease
- Symptomatology, Evidence of decompensation (jaundice, organomegaly, encephalopathy, ascites, infections, variceal bleed etc)
- PELD, MELD Na score, Lansky play performance score
- Baseline laboratory parameters: Complete blood count, LFT, KFT, PT-INR, ammonia etc
- Imaging parameters: liver and spleen size, portal vein size etc
- Anthropometric parameters:
- Weight for age
- Height for age
- BMI
- Triceps skin fold thickness
- Subscapular fold thickness
- Mid arm circumference
Calculation of frailty score:
Cut-off for frailty will be defined as frailty score >5 in children with liver disease.
Methodology for Frailty assessment:
Assessment of the 5 Fried Frailty Criteria would be performed at baseline in an ambulatory setting .The Fried Frailty assessment would be done in children with liver disease. The assessments will be typically performed by a combination of a doctor, dietician and physiotherapist.
Weakness-Grip strength would be measured using a handheld device, the Jamar Hand Dynamometer. The device would be squeezed 3 times by each hand, and the mean value of the recorded strength (in pounds) was taken as the final result and compared with standard values for age and sex. Slownessor endurance would be assessed by the 6-minute walk test (6-MWT). Children will use a standard hand wheel to capture the walked distance on a hard flat surface at their own pace. The covered distance expressed in meters (m) will be compared with standard values for sex and age. Shrinkage in children would be assessed by triceps skin fold thickness (TSF) measurements. TSF would be measured in triplicates by a dietician and the mean result was recorded in centimeters (cm) and compared with the Center for Disease Control age and sex normative values. Exhaustion-the Pediatric Quality of Life Inventory 4.0 Multidimensional Fatigue Scale, a validated pediatric questionnaire, would be used to assess fatigue. Diminished Physical activity-For children the age appropriate versions of the validated Modified Physical Activity Questionnaire (PAQ) (PAQ-A for children >13 years of age and PAQ-C for children< 13 yearof age will be used .
Along with routine investigations including Complete Blood counts, Liver function and Renal function test, PT-INR, serum Ammonia, the following investigations will also be done:
- Myokines (myostatin, decorin, irisin) and hepatokines (follistatin) levels in blood and urine at baseline and after 12 weeks of exercise therapy in study 2.
- Body composition analysis: Following parameters would be assessed: skeletal Muscle Mass; Body fat Mass; whole Body phase angle; segmental lean Analysis at baseline and after 12 weeks of exercise therapy in study 2.
Following enrolment and those fulfilling inclusion criteria, patient will then be allocated into exercise with SMT or SMT alone group as per block randomization method. Exercise with SMT or SMT alone will be given for a period of 12 weeks. Patient will be followed up for a period of 12 weeks. At the end of 12 weeks, frailty score will be recalculated .Body composition analysis,myokines and hepatokines will be repeated after 12 weeks.
Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed and overall hospital stay as well as mortality over 12 weeks and 6 months will be noted in both groups during this period and treated as per standard of care. These events will be defined as follows-
- Acute Kidney Injury As per KDIGO guidelines:
- Increase in serum creatinine by more than 0.3mg/dl within 48 hours, OR
- Urine output less than 0.5ml/kg/hour for more than 6 hours, OR
- Increase in serum creatinine by more than 1.5 times the baseline presumed/known to have occurred within prior 7 days.
- Hepatic encephalopathy: as per Modified West-Haven's criteria.
- Grades of ascites Grade 1- ascites only detected by ultrasound Grade 2 -moderate ascites evident by distension of abdomen with shifting dullness Grade 3- gross/tense ascites with marked abdominal distension Study period: 2 years
Intervention (Study 2):
- Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc
- Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol)
- Aerobic exercises consist of Brisk walking
- Resistance Exercises consist of movements targeting the major muscle groups with weight lifting
- Intensity:
Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10.
- Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength End point: 12 weeks
Stopping rule:
- Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events.
- Progression to exclusion criteria i.e. decompensation etc Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day, and this will be ensured in regular follow-up as a standard care of practice developed by the department of Pediatric Hepatology.
Monitoring and assessment:
Patients will be followed up for a period of at least 3 months. Occurrence of clinical events including new onset ascites, AKI, hepatic encephalopathy, upper GI bleed, significant infections will be noted in both groups during this period and treated as per standard of care.
At the end of 12 weeks, frailty assessment will be repeated along with myokines and hepatokines, body composition analysis and anthropometric examination.
Adverse effects:
There are no expected adverse effects of exercise as seen in previous studies.
Stopping rule of study:
- Interruption of exercise for more than 7 consecutive days due to non-compliance or clinical events.
- Progression to exclusion criteria i.e decompensation
- Potential liver transplant within 1 month.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Subject will receive 12 weeks of exercise with standard medical management (SMT) | Experimental | Other: 12 weeks exercise, Other: Standard Medical Treatment* Subjects will be given exercise protocol Pre-exercise safety assessment: Careful assessment as per exclusion criteria; especially Portal Hypertension, Cardiopulmonary status etc * Frequency: Aerobic and Resistance Exercises for total 50 minutes/day for 2-5 days per week (see protocol) * Aerobic exercises consist of Brisk walking * Resistance Exercises consist of movements targeting the major muscle groups with weight lifting * Intensity: Talk test: Short of breath but still can speak a full sentence Borg Scale: Keep between 5-6 out of 10. * Time duration of aerobic exercise decided by 6MWT, and resistance exercise by Hand grip strength * End point: 12 weeks * Stopping rule: * Interruption of Exercise for > 7 consecutive days due to non-compliance or clinical events. * Progression to exclusion criteria i.e. decompensation etc Both groups will be advised a calorie intake of 150cal/kg/day and protein intake of 3 gm/kg/day |
| standard medical management (SMT) | Active comparator | Other: Standard Medical Treatmentstandard medical management (SMT) |
Who may qualify
- Ages
- 9 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Children 9 - 18 years age with chronic liver disease \& frailty score > 5.
Key exclusion criteria (13 listed)
- Lansky play performance scale <50
- Unable to do exercise under supervision on at least 2 occasions
- Children on higher corticosteroid dose (>0.1mg/kg/day) in last 12 weeks
- Any degree of musculoskeletal involvement (myopathy/limb deformity/paraplegia)
- Children with any cardiac disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 12 weeks exercise12 weeks exercise | Other | Subject will receive 12 weeks of exercise with standard medical management (SMT) |
| Standard Medical TreatmentStandard Medical Treatment | Other | Subject will receive 12 weeks of exercise with standard medical management (SMT), standard medical management (SMT) |
Primary outcome
Prevalence of Frailty in children with liver disease.
Time frame: 0 day
Fraility assessment criteria will be based on 5 elements: 1. weakness will be assessed by grip strength. 2. slowness will be by 6 minutes walk test. 3. shrinkage by triceps fold thickness. 4. exhaustion by validated pediatric PedsQL 4.0 multidiamential fatigue scale. 5. diminshed physical activity by modified PAQ
Improvement in Frailty after 12 weeks of exercise therapy in children with CLD and Frailty.
Time frame: 12 weeks
Improvement will be based on five fried fraility criteria with fraility score> 5
9 secondary outcomes
Increase in skeletal muscle mass in Body composition analysis after 12 weeks of exercise regimen
Time frame: 12 weeks
Decrease in the occurrence of Hepatic Encephalopathy based on modified West Haven criteria in the exercise regimen with SMT group versus SMT alone.
Time frame: 3 months
Decrease in the occurrence of Upper Gastrointestinal bleed (presence or absence of GI bleed) in the exercise regimen with SMT group versus SMT alone.
Time frame: 3 months
Decrease in the occurrence of significant events including Spontaneous Bacterial Peritonitis in the exercise regimen with SMT group versus SMT alone .
Time frame: 3 months
Decrease in the occurrence of significant events including Acute Kidney Injury in the exercise regimen with SMT group versus SMT alone .
Time frame: 3 months
Decrease in the occurrence of significant events including new onset or increase in ascites in the exercise regimen with SMT group versus SMT alone .
Time frame: 3 months
Decrease in the occurrence of significant events including hospital stay in the exercise regimen with SMT group versus SMT alone .
Time frame: 3 months
Decrease in the occurrence of significant events including mortality in the exercise regimen with SMT group versus SMT alone .
Time frame: 3 months
Decrease in myostatin levels after 12 weeks of exercise regimen
Time frame: 12 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2025.
Related trials for Liver Diseases
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Active, not recruitingPhase 2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Chronic Hepatitis B Virus Infection, Hepatitis B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 12 weeks exercise and Standard Medical Treatment in people with Liver Diseases, run by Institute of Liver and Biliary Sciences, India at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Frailty in children with liver disease. (time frame: 0 day). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2025.